Success Story: Dual NIW & EB1A Success for a Staff Scientist with Premium Processing and Our Swift Filing
Client’s Testimonial:
"It was a pleasure working with you. I greatly appreciate your patience throughout case preparation and case filing. I will definitely recommend your services to my friends.”
On October 24th, 2024, and January 30th, we received EB-2 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) approvals for a Staff Scientist in the Field of Medical Biochemistry (Approval Notice).
General Field: Medical Biochemistry
Position at the Time of Case Filing: Staff Scientist
Country of Origin: India
State of Residence at the Time of Filing: Missouri
Approval Notice Date: October 24th, 2024 & January 30th,2025 (NIW&EB1A)
Processing Time: 1 month, 15 days (NIW), and 22 days (EB1A) (Premium Processing Requested)
Case Summary:
We are pleased to share another outstanding approval secured by our team: a dual-success outcome for a distinguished medical biochemist whose I-140 NIW (National Interest Waiver) and I-140 EB-1A (Alien of Extraordinary Ability) petitions were both approved through premium processing. These decisions underline the national importance of innovative biomedical research advancing cancer therapeutics and precision medicine.
The client holds a Ph.D. in medical biochemistry and has built an exceptional career at the intersection of pharmacokinetics/pharmacodynamics (PK/PD), drug discovery, molecular imaging, and pharmacogenomics. A core focus of the client’s scientific contribution is uncovering how natural compounds, particularly free ginger phenolics, can disrupt cancer progression, ultimately supporting new therapeutic strategies for treating drug-resistant tumors.
Both petitions demonstrated the client’s influential record and continuing contributions to pressing U.S. health priorities such as cancer research, disease prevention, and improved drug safety. These achievements include:
- 12 peer-reviewed journal articles (including 5 first-authored)
- 9 peer-reviewed abstracts (including 7 first-authored)
- 1 book chapter
- 420 citations by researchers around the world
- 13 completed peer reviews for high-caliber journals
The petitions highlighted how the client’s research advances fundamental understanding of tumor behavior, supports innovative imaging-based diagnostic approaches, and informs safer, more effective therapeutic development. By applying advanced compound characterization and PK/PD modeling, the client has demonstrated how promising compounds enter tumors, interact with biological tissues, and can be engineered for improved cancer treatment outcomes.
As part of the petitions, four independent recommendation letters were submitted from established experts in medical biochemistry and related disciplines. Each recommender confirmed that the client’s scientific findings have guided the research of peers globally and accelerated the pursuit of next-generation cancer therapies.
“Given the urgent need for improved diagnostic tools and targeted therapies for asthma and related allergic conditions, it is clear there is a need for further advances with respect to these issues. As [Client] has produced highly valuable research in this regard, there is an ongoing demand for her particular expertise.”
The approvals, first for NIW and then for EB-1A, affirm USCIS’s recognition that the client has risen to the top of the field and will continue to produce impactful, nationally beneficial research. The client’s ongoing work contributes to a stronger biomedical innovation ecosystem in the United States, supporting improved cancer care and transformative health advancements.
We are honored to have represented this exceptional scientist and look forward to witnessing continued breakthroughs in lifesaving cancer therapies driven by their research.